Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Hemp-derived CBD:CBD-A 1:1 Oral Product
NCT05049733Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zygel and cannabidiolic acid (4 arms), sponsored by Johns Hopkins University. Primary endpoints: Maximum Plasma Concentration at 48 hours, Area Under the Curve at 48 hours and 1 more. Started Mar 2022; status: completed.
02
Drugs
Zygelcannabidiolic acid
Beyond the preview
Go deeper on NCT05049733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049733.